NanobacTX is a patented non-prescription oral nanobiotic compound shown in published cardiology studies to help improve cardiovascular health and lipid profiles. Published IRB-Monitored, peer-reviewed cardiology clinical trial results show that NanobacTX helps improve vascular health, heart health and increases exercise ability. NanobacTX can help improve cardiovascular function, coronary blood flow and vascular flexibility. NanobacTX should be taken for 6-12 months of nightly treatment of 8 capsules/night. Thereafter, a maintenance program dosage of 1-2 capsules/night is required for continued benefit.

Order 3 Bottles or More & Save! Place an order for 3 or more bottles (3 bottles = a 90 day supply), and receive a discount of $20 per bottle at check out.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

• 
  
  

  Other Ingredients: Cellulose, Mg Stearate & Silicon Dioxide.

  PLEASE FOLLOW THESE IMPORTANT INSTRUCTIONS WHEN USING NANOBACTX:

  1. You can continue to take vitamin and mineral supplements. However, do not take any supplements after 12 Noon. The manufacturer�s research has shown that taking vitamin or mineral supplements at night could decrease the effectiveness of NanobacTX.
  2. We recommend a normal breakfast, a normal lunch and a very light evening meal.
  3. NanobacTX must be taken at bedtime.
  4. Store your bottle of NanobacTX in a cool and dry place. You may store it in the refrigerator, but never the freezer.
  5. For optimal absorption, NanobacTX Capsules must be swallowed whole and not emptied into beverages or foods.

  Adult Dosage: Take 8 capsules every night AT BEDTIME with 6-16 ounces of clear apple juice or cool water. For ideal efficacy, take your capsules at least two hours after your evening meal. After taking the dose, lie down and go to sleep.

  After an initial core therapy of 6-12 months of continuous full-strength use, a low�dose maintenance program is important. The Maintenance Dose is usually 1-2 capsules per night or as directed by your physician.

  Our oral formula has improved patient tolerance & bioavailability compared to the original version. The unique patented capsules bypass the stomach�s acidity and allow for dissolution at ideal pH in the small bowel. This promotes the highest possible absorption, bioavailability and efficacy.

  Side Effects: Adverse side effects are extremely rare, uncommon, minimal and generally limited to gas or loose stool that resolves within 7 days. Most people have no adverse symptoms.

  NanobacTX contains 240 vegetarian capsules per bottle. The capsules are a regulated delayed-release capsule that is acid-resistant to allow for optimal absorption by the small intestine.

  A note on CAC testing: If you have a family history of coronary heart disease, Dr. Grossman recommends baseline screening at 40 for men and 45 for women. In the absence of such history, baseline screening is recommended at 45 for men and 50 for women.
  (Note that there is radiation involved in this test and we do not recommend it for frequent use.)

  This product is not a substitute for any Rx meds. This product is not intended for pregnant or nursing mothers, children under the age of 18, or persons with a known medical condition. If you have questions about the advisability of taking this product, consult your physician prior to use.

  Store at room temperature. Avoid prolonged exposure to excessive heat or moisture.

  NanobacTX is manufactured at an FDA-licensed pharmaceutical manufacturing facility according to strict Good Manufacturing Practices.

  
  

An Important Independent Summary of Scientific Research & Clinical Studies: Anton Kutikin, PhD in The International Journal of NanoMedicine "The Role of CNPs in Biology & Medicine" www.ncbi.nlm.nih.gov/pmc/articles/PMC3266001

(Please note that for publishing purposes, our Nanobiotics were referred-to as comET as a generic name and not our actual tradenames of NanobacTX & Urobac. Scientific publications allow only the use of generic names and not trademark names.)

Published Science & Clinical Studies:

Maniscalco, B.S., NanobacTX Cardiology Study. Intl Journal of Pathophysiology.11(2): 95-101.

Puskas, L. G., L. Tiszlavicz, Zs Razga, L. Torday, T. Krenacs, J. G Papp. Detection of nanobacteria-like particles in human atherosclerotic plaques. Acta Biologica Hungarica56 (3-4): 233-245.

Jelic T. M., A. M. Malas, S. S. Groves, B. Jin, P. F. Mellen, G. Osborne, R. Roque, J. G. Rosencrance, and H. H. Chang. Nanobacteria-caused mitral valve calciphylaxis in a man with diabetic renal failure.South Med J.Feb; 97 (2): 194- 198.

Lieske J. C., V. Kumar, G. Farell-Baril, S. Yu, J. E. Charlesworth, E. Rzewusk-Lech, P. LaBreche, S. R. Severson, and V. M. Miller. Mayo Clinic.Detection and propagation of calcified nanostructures from human aneurysm.J Am Coll Cardiol Abstracts Book.1059-13: 13A.

Miller, V. M., G. Rodgers, J. A. Charlesworth, B. Kirkland, S. R. Severson, T. E. Rasmussen, M. Yagubyan, J. C. Rodgers, F. R Cockerill, III, R. L. Folk, V. Kumar, G. Farell-Baril, J. C. Lieske. MAYO CLINIC. Evidence of nanobacterial-like structures in human calcified arteries and cardiac valves. Am J Physiol Heart Circ Physiol.287 (3): H1115-24.

Kajander, E O.Nanobacteria do exist and actively participate in the calcification of arterial plaque.Townsend Letter 234:80-82.

Ciftcioglu, N., M. A. Miller-Hjelle. J. T. Hjelle and E. O. Kajander. Inhibition of Nanobacteria as measured by a modified microdilution method.Antimicrob Agents Chemother.46: 2077-2086.

Kajander, E. O., K. Aho and V. Segal. Apatite biofilm forming agent: nanobacteria as a model system for biomineralization and biological standard for noa, a preliminary study.Proceedings of the 2nd International Conference on Near-Field Optical analysis. Houston, Texas.

Rasmussen, T. E., B. L. Kirkland, J. Charlesworth, et al.Electron microscope and immunological evidence of nanobacteria in calcified carotid arteries, aortic aneurysms and cardiac valves.J Am Coll Cardiol Abstracts Book.1009-79: 206A.

Ciftcioglu, N., V. Ciftcioglu, H. Vali, E. Turcott, E. O. Kajander. Sedimentary rocks in our mouth: dental pulp stones made by nanobacteria. Proc. SPIE.3441: 130-135.